Original research

Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up

Anna A Herasimtschuk¹ , Samantha J Westrop¹ , Graeme J Moyle² , Jocelyn S Downey¹ and Nesrina Imami¹

¹  Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK

²  Department of HIV/GU Medicine, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK

author email corresponding author email

Journal of Immune Based Therapies and Vaccines 2008, 6:7doi:10.1186/1476-8518-6-7

Published:	31 October 2008

Abstract

Background

Efficacious immune-based therapy in treated chronic HIV-1 infection requires the induction of virus-specific CD4⁺ T cells and subsequent maturation and maintenance of specific memory CD8⁺ T cells. Concomitant daily administration of recombinant human growth hormone (rhGH) with highly active antiretroviral therapy (HAART) was used in chronically infected patients with lipodystrophy in an attempt to reconstitute these virus-specific T-cell responses.

Methods

Individuals with chronic HIV-1 infection on HAART were enrolled on a randomized, double-blinded, placebo-controlled study to receive rhGH therapy. We assessed HIV-1-specific proliferative CD4⁺ and interferon-gamma (IFN-γ)-producing CD8⁺ T-cell responses, quantified thymic output and proviral HIV-1 DNA at the following time points: baseline; after 12 weeks of rhGH therapy; at 24 weeks, after randomization into three groups [placebo weeks 12–24 (Group A), alternate-day dosing weeks 12–24 (Group B), and twice-per-week dosing weeks 12–24 (Group C)]; and at 48 weeks after all patients had received HAART alone for the final 24 weeks.

Results

We found significant increases in both proliferative CD4⁺ and IFN-γ-producing CD8⁺ HIV-1-specific T-cell responses after daily administration of rhGH. This increase was focused on HIV-1 Gag-specific T-cell responses. Following subsequent randomisation into different dosing regimens, HIV-1-specific proliferative CD4⁺ T-cell responses declined in patients receiving less frequent dosing of rhGH, while virus-specific IFN-γ-producing CD8⁺ T-cell responses were maintained for longer periods of time. There was no significant change in thymic output and the cell-associated HIV-1 DNA remained stable in most patients. An increased anti-HIV-1 Nef-specific CD4⁺ T-cell proliferative response was correlated to a decrease in proviral load, and an increased HIV-1 Gag-specific IFN-γ-producing CD8⁺ T-cell response correlated with an increase in proviral load.

Conclusion

The implication of these data is that daily dosing of rhGH with HAART, in addition to improving HIV-1-associated lipodystrophy, may reverse some of the T-lymphocyte dysfunction seen in most treated HIV-1-positive patients, in a dose-dependent manner. Such immune-based therapeutic strategies used in treated, chronic HIV-1 infection may enable the induction of virus-specific CD4⁺ T cells essential for the subsequent 'kick-start' and expansion of virus-specific CD8⁺ T cells.

Trial registration

GH in Lipoatrophy IMP22350.